Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29.
No abstract available

Keywords: DMARDs (synthetic); methotrexate; rheumatoid arthritis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnosis*
  • Arthritis, Rheumatoid / drug therapy
  • Biomarkers / analysis
  • Decision Support Techniques*
  • Female
  • Humans
  • Male
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Risk Assessment / methods
  • Severity of Illness Index
  • Treatment Outcome
  • Vascular Cell Adhesion Molecule-1 / analysis

Substances

  • Antirheumatic Agents
  • Biomarkers
  • Vascular Cell Adhesion Molecule-1
  • Methotrexate